2期抗癌药物研发商Starton Holdings(STA.US)IPO定价5-7美元 拟融资4000万美元

Core Viewpoint - Starton Holdings is planning to raise up to $40 million through an initial public offering (IPO) by issuing 6.7 million shares at a price range of $5 to $7, with a fully diluted market capitalization of approximately $262 million at the midpoint of the proposed price range [1] Company Overview - Starton Holdings is a biotechnology company focused on developing approved cancer drug delivery systems, currently in Phase II clinical trials [1] - The company utilizes continuous delivery technology to enhance FDA-approved active ingredients for cancer treatment, following the FDA's 505(b)(2) regulatory pathway [1] - The company is headquartered in Paramus, New Jersey, and was established in 2017, planning to list on NASDAQ under the ticker symbol STA [2] Product Focus - The main project, "STAR-LLD," targets multiple myeloma and chronic lymphocytic leukemia, aiming to develop subcutaneous and oral controlled-release formulations of lenalidomide, a generic version of Revlimid [1] - Starton Holdings is also exploring the potential combination of STAR-LLD with CAR-T therapy and expanding into other cancer types, including B-cell lymphoma and solid tumors [1] Financial Details - The IPO aims to raise a total of $40 million through the issuance of 6.7 million shares, with the proposed price range set between $5 and $7 [1]